A don’t miss opportunity to join your peers and colleagues for a LIVE 1.0 CNE educational event to learn about the latest updates in ALL and LBL. These educational events are designed to be highly interactive and engaging.
New Dates to be Announced!
Chair & Presenter
Dr. Sandra Kurtin Sandra Kurtin, PhD, ANP-C, AOCN, FAPO
Assistant Professor of Clinical Medicine
Adjunct Clinical Assistant Professor of Nursing
The University of Arizona College of Medicine
Director of Advanced Practice
Hematology/Oncology Nurse Practitioner
The University of Arizona Cancer Center
Tucson, Arizona

Program Overview

Join this highly engaging and interactive live discussion on the evolving role of asparaginase therapies in acute lymphocytic leukemia (ALL) and lymphoblastic lymphoma (LBL). This educational event is specifically designed for oncology nurses that care for adolescents and young adults (AYA) and adult patients.

Participants will learn about the current guidelines on the use of asparaginase and how to implement strategies for managing hypersensitivity reactions. In addition, our expert will discuss how to monitor patients for the development of asparaginase hypersensitivity and silent inactivation.

This program will conclude with a Q&A session. Don’t miss the chance to ask an expert your questions regarding practice.

Agenda

5 minutes Introduction and Baseline Assessment
20 minutes Currently Available Treatment Options and the Evolving Role of Asparaginase in ALL and LBL
20 minutes Recognizing and Managing Unique Asparaginase Toxicities
5 minutes Interactive Discussion: Clinical Nursing Pearls for the Effective Management of Pediatric, AYA and Adult ALL and LBL Patients
10 minutes Conclusion, Q&A and Assessment

Target Audience
This educational activity is designed for oncology nurses who provide care to patients with pediatric, AYA and adult patients with ALL or LBL.

Learning Objectives
Upon completion of this educational activity, participants should be able to:

  • Summarize current guidelines on the use of asparaginase-containing treatment regimens in adolescents, young adults, and adults with ALL and LBL
  • Implement strategies for managing hypersensitivity reactions in patients with ALL and LBL including the use of serum asparaginase activity (SAA) levels
  • Educate patients and families on the importance of prompt identification and management of hypersensitivity reactions

Accreditation

MediCom Worldwide, Inc. Nursing Credit
MediCom Worldwide, Inc. is approved by the California Board of Registered Nursing, Provider Number CEP11380. MediCom designates this CNE activity for 1.0 contact hour. Program Number: 23-010-166

Disclosure
As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is in a position to control the content of an accredited continuing education activity to disclose all financial relationships with any ineligible company. The ACCME defines “ineligible companies” as any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products by or on patients. A relevant relationship exists if a financial relationship in any amount exists between the person in control of content and an ineligible company; the financial relationship existed during the past 24 months and the content of the education is related to the products of an ineligible company with whom the person has a financial relationship. MediCom will identify mitigation strategies for all persons with relevant financial relationships who control content of the educational activity.

Faculty Disclosures
Dr. Sandra Kurtin has relevant financial relationships related to consulting from AbbVie Inc., Agios, Inc., Amgen Inc., AstraZeneca, Bristol Myers Squibb Company, GlaxoSmithKline plc, and Takeda Oncology.

All of the relevant financial relationships listed for the individual has been mitigated.

Unapproved Product Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses of products or devices.
 Planning Committee
Joan Meyer, RN, MHA, Executive Director, and Cassie Rametta, Senior Program Manager, planners for this educational activity, have no relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, reselling, or distributing healthcare products used by or on patients.

Peer Reviewer
Peer reviewer(s) for this educational activity have no relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, reselling, or distributing healthcare products used by or on patients.

Instructions for Participation and Credit

There are no fees for participating in this activity.

In order to receive credit, all participants must complete the self-assessment post-test and Activity Evaluation following the activity. Partial credit will not be awarded for this activity. Participants must receive a minimum score of 70% on the self-assessment to qualify for CNE credit.

CNE Credit certificates will be emailed 4 weeks following receipt of completed requirements.

If you have any questions regarding the content of this activity, please contact MediCom Worldwide, Inc. at 800-408-4242, x114 or [email protected].
Provided by
MediCom Worldwide, Inc. Supported by an independent medical education grant from Jazz Pharmaceuticals.
©2023 MediCom Worldwide, Inc., 660 Newtown Yardley Rd, Suite 203 · Newtown, PA 18940, 800-408-4242. No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.